|
|
 |
|
Viewing report
|
|
|
|
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
Arrowhead Publishers, Dec 2005, Pages: 261
Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.
Our new report entitled Cancer Therapeutics 2006: Market Dynamics and R&D Trends examines these four major cancer markets in light of newly emerging therapeutics, shifting market shares and line extensions for major products on the market.
Features of this Report
- market analysis by class, cancer type, product, company, and geographic region
- sales data from 2000 through Sept 2005 as well as full-year 2005 estimates
- profiles of leading products in the four major cancer markets and analysis of their market impact
- presentation and analysis of clinical data underscoring success of key therapies
- market share data for leading companies and products in the field
- SWOT analysis for key products in each market
- profiles of key emerging therapies and clinical data supporting development
- financial forecasts for the four major cancer markets
- 133 tables/graphs/diagrams illustrating historical sales data, growth rates and market share by product, class, therapeutic category, and company, company portfolios, pipelines, clinical efficacy data, as well as epidemiologic
data
Additionally, Cancer Therapeutics 2006 offers readers a critical examination of emerging and pipeline products in colorectal, prostate, lung, and breast cancer. Pipeline products with the greatest potential are assessed for their
clinical efficacy and possible market impact. Briefs are provided for companies that are either firmly entrenched in one of these four cancer markets or are developing groundbreaking new drugs that are being designed to treat not only one of the leading four cancers, but other cancers as well.
Key Findings
The market for colorectal cancer therapies has increased by over seven-fold since 2000. The increase in the value of this market can be explained by new and improved chemotherapeutic agents now on the market, the introduction of key biologic therapies, and improved chemotherapeutic regimens which take into account various new options.
The value of the prostate cancer therapy market is over $2.6 billion in 2005. Hormone therapies continue to dominate the market, as they have proven to be the most effective at treating later-stage prostate cancer and are usually second in line to radiation therapy for patients with locally-advanced disease. However, with the looming approval of vaccines, angiogenesis inhibitors, and increased use of chemotherapy in metastatic disease, future treatment will take into account the benefits and disadvantages associated with ALL of these therapies.
The market for the pharmaceutical treatment of lung cancer is still largely dominated by cytotoxics in 2005-2006, although targeted therapies are beginning to make an impact. Continued uptake of Tarceva and potential approvals for Avastin, Zactima, Erbitux and other new therapies will offset the decline in value that has come as a result of patent expirations in this market.
The breast cancer market is the most vibrant and dynamic of the four major cancer markets. Currently, the market is divided between chemotherapeutic agents, anti-hormonals, and Herceptin. The strongest growth in recent years has been in the anti-hormonal sector. The overall value of branded products should increase significantly during the next five years. Uptake of aromatase inhibitors, targeted therapies, and new cytotoxic combinations should increase patient options and result in increased competition and better clinical outcomes in this dynamic market.
|
|
|
|
